FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. - Sharma P; Kanapuru B; George B; Lin X; Xu Z; Bryan WW; Pazdur R; Theoret MR (Clinical cancer research : an official journal of the American Association for Cancer Research, 2022)